GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Earnings Power Value (EPV)

MedMira (MedMira) Earnings Power Value (EPV) : $-0.04 (As of Jan24)


View and export this data going back to . Start your Free Trial

What is MedMira Earnings Power Value (EPV)?

As of Jan24, MedMira's earnings power value is $-0.04. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


MedMira Earnings Power Value (EPV) Historical Data

The historical data trend for MedMira's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Earnings Power Value (EPV) Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.05 - - -

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedMira's Earnings Power Value (EPV)

For the Biotechnology subindustry, MedMira's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Earnings Power Value (EPV) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where MedMira's Earnings Power Value (EPV) falls into.



MedMira Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

MedMira's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 0.76
DDA 0.14
Operating Margin % -313.37
SGA * 25% 0.18
Tax Rate % 0.00
Maintenance Capex 0.00
Cash and Cash Equivalents 0.64
Short-Term Debt 4.68
Long-Term Debt 1.97
Shares Outstanding (Diluted) 698.09

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -313.37%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $0.76 Mil, Average Operating Margin = -313.37%, Average Adjusted SGA = 0.18,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 0.76 * -313.37% +0.18 = $-2.190908311 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 0.00%, and "Normalized" EBIT = $-2.190908311 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -2.190908311 * ( 1 - 0.00% ) = $-2.190908311 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 0.14 * 0.5 * 0.00% = $0 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -2.190908311 + 0 = $-2.190908311 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
MedMira's Average Maintenance CAPEX = $0.00 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. MedMira's current cash and cash equivalent = $0.64 Mil.
MedMira's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 1.97 + 4.68 = $6.651 Mil.
MedMira's current Shares Outstanding (Diluted Average) = 698.09 Mil.

MedMira's Earnings Power Value (EPV) for Jan24 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -2.190908311 - 0.00)/ 9%+0.64-6.651 )/698.09
=-0.04

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -0.043487963806537-0.06 )/-0.043487963806537
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.


MedMira  (OTCPK:MMIRF) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


MedMira Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of MedMira's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports First Quarter Results FY2023

By ACCESSWIRE ACCESSWIRE 12-31-2022

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

MedMira Reports First Quarter Results FY2024

By ACCESSWIRE 12-30-2023

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

By ACCESSWIRE ACCESSWIRE 10-14-2022